<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5722">
  <stage>Registered</stage>
  <submitdate>17/02/2015</submitdate>
  <approvaldate>17/02/2015</approvaldate>
  <nctid>NCT02369016</nctid>
  <trial_identification>
    <studytitle>Phase III Copanlisib in Rituximab-refractory iNHL</studytitle>
    <scientifictitle>A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2</scientifictitle>
    <utrn />
    <trialacronym>CHRONOS-2</trialacronym>
    <secondaryid>2014-000925-19</secondaryid>
    <secondaryid>17322</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma, Non-Hodgkin</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Copanlisib (BAY 80-6946)

Experimental: Copanlisib (BAY 80-6946) - 60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle


Treatment: drugs: Copanlisib (BAY 80-6946)
60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Tumor Response Rate (ORR) - Objective tumor response rate (ORR) is defined as the proportion of patients who have a best response rating up to the dates of data analysis of complete response (CR) or partial response (PR) according to the Lugano Classification, and for patients with WM, a response rating of CR, very good partial response (VGPR), PR, or minor response (MR) according to the Owen criteria.</outcome>
      <timepoint>After all treated patients complete at least 6 Cycles (one cycle is 28 days) of study treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) - Defined as the time (in days) from first observed tumor response (Complete Response, Very Good Partial Response, Partial Response or Minor Response) until PD (Progressive disease) or death from any cause, whichever is earlier.</outcome>
      <timepoint>After all treated patients complete at least 6 cycles of study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete response rate (CRR) - Defined as patients who have a best response up to the dates of analysis of complete response (CR) according to the Lugano Classification, and for patients with WM, a response rating of CR according to the Owen criteria.</outcome>
      <timepoint>After all treated patients complete at least 6 cycles of study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS) - Defined as the time (in days) from randomization until death from any cause. OS of patients alive at the time of analysis will be censored at the last date they were known to be alive.</outcome>
      <timepoint>Up to 3 years after the last patient started study treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype
             limited to the following:

               -  Follicular lymphoma (FL) grade 1-2-3a.

               -  Small lymphocytic lymphoma (SLL) with absolute lymphocyte count &lt; 5 x 10*9/L at
                  the time of diagnosis and at study entry.

               -  Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM).

               -  Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal).

          -  Patients must have received two or more prior lines of treatment. A previous regimen
             is defined as one of the following: at least two months of single-agent therapy, at
             least two consecutive cycles of polychemotherapy, autologous transplant,
             radioimmunotherapy.

          -  Prior therapy must include rituximab and alkylating agents.Prior exposure to
             idelalisib or other PI3K inhibitors is acceptable (except to copanlisib) provided that
             there is no resistance.

          -  Patients must be refractory to the last rituximab-based treatment, defined as no
             response or response lasting &lt; 6 months after completion of treatment. Time interval
             to assess refractoriness will be calculated between the end date (last day) of the
             last rituximab-containing regimen and the day of diagnosis confirmation of the
             subsequent relapse.

          -  Patients must have at least one bi-dimensionally measurable lesion (which has not been
             previously irradiated) according to the Recommendations for Initial Evaluation,
             Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano
             Classification.

          -  Patients affected by WM, who do not have at least one bi-dimensionally measurable
             lesion in the baseline radiologic assessment, must have measurable disease, defined as
             presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level = 2 x upper
             limit of normal (ULN)and positive immunofixation test.

          -  ECOG performance status = 1

          -  Adequate bone marrow, liver and renal function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Histologically confirmed diagnosis of FL grade 3b.

          -  Chronic lymphocytic leukemia (CLL).

          -  Transformed disease (assessed by investigator):

               -  histological confirmation of transformation, or

               -  clinical and laboratory signs: rapid disease progression, high standardized
                  uptake value (SUV) (&gt; 12) by positron emission tomography (PET) at baseline if
                  PET scans are performed (optional).

          -  Bulky disease - Lymph nodes or tumor mass (except spleen) &gt;= 7cm LD (longest diameter)

          -  Known lymphomatous involvement of the central nervous system.

          -  Uncontrolled arterial hypertension despite optimal medical management (per
             investigator's assessment).

          -  Type I or II diabetes mellitus with HbA1c &gt; 8.5% at Screening.

          -  Known history of human immunodeficiency virus (HIV) infection.

          -  Active clinically serious infections &gt; CTCAE Grade 2

          -  Active Hepatitis B or hepatitis C

          -  History or concurrent condition of interstitial lung disease of any severity and/or
             severely impaired lung function (as judged by the investigator)

          -  History of having received an allogeneic bone marrow or organ transplant

          -  Positive cytomegalovirus (CMV) PCR test at baseline

          -  Pregnant or breast-feeding patients</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>22/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>7/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Chaco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Auton. de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vorarlberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belarus</country>
      <state>Lesnoy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belarus</country>
      <state>Minsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Goiás</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Parana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Araucanía</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Heilongjiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jiangsu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Zhejiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Tianjin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Antioquia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Medellín</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>France</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-denis Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Haidari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Piraeus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Liguria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeollabuk-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeollanam-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Michoacán</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Oaxaca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Almada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Vila Nova de Gaia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Arkhangelsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Chelyabinsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Engels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kemerovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnoyarsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Orel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Penza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Petrozavodsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Dammam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Jeddah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Makkah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Eastern Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Denizli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Khmel'nytsky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Assess the efficacy and safety of copanlisib monotherapy</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02369016</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>